DocWire News Editors

DocwireNews

Two poster presentations to be shared at AAO 2019 will aim to shed light on polypoidal choroidal vasculopathy (PCV) treatments and adverse events.The first, &ldquo;ATLANTIC Study: Aflibercept Monotherapy vs. Aflibercept With PDT in Polypoidal Choroidal Vasculopathy,&rdquo; compared intravitreal aflibercept treat-and-extend (IVA-TAE) plus sham photodynamic therapy (sPDT) to IVA-TAE with verteporfin PDT (vPDT) in PCV patients. The randomized, double-masked, sham-controlled, Phase 4 investigator-driven clinical trial spanned 52 weeks and 14 centers in Portugal and Spain. PCV patients received IVA 2 mg plus sPDT or IVA 2 mg plus vPDT. The main outcomes were change in best corrected visual acuity (BCVA) compared to baseline and 52-week polyp regression.Final analysis included 50 patients (mean age, 72.6 &plusmn; 9.2 years; all patients were white) with a mean baseline BCVA of 62.8 &plusmn; 12.1 ETDRS letters. After 16 weeks, 42% of eyes needed PDT; only one patient required subsequently PDT. BCVA gains and polyps regression did not largely differ at final follow-up. The authors concluded that PDT did not provide any functional or anatomic benefit at one year in this PCV patient population.The second study, &ldquo;Incidence Rate of Massive Submacular Hemorrhage and Its Risk Factors in Polypoidal Choroidal Vasculopathy and Typical nAMD,&rdquo; analyzed the incidence rate of and risk factors associated with massive submacular hemorrhage in patients with PCV and typical neovascular AMD (tnAMD). This retrospective study included 465 total patients (PCV, n = 245; tnAMD, n = 220). Cumulative incidences of and associated risk factors with massive submacular hemorrhage were evaluated.Overall, 32 PCV patients and nine tnAMD patients developed massive submacular hemorrhage. From the initial visit, one-, five-, and 10-year incidence rates of massive submacular hemorrhage in PCV patients were 2.5%, 11.1%, and 29.9%, respectively, and in tnAMD patients were 1.8%, 4.3%, and 9.9%, respectively&mdash;presenting a significantly higher incidence rate in PCV than in tnAMD (P = 0.007). The most significant risk factor in PCV patients was mean number of annual photodynamic therapies (hazard ratio [HR] = 4.24), and for tnAMD patients was mean number of annual anti- vascular endothelial growth factor injections (HR = 1.58).

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Roger Rodby, MD

Seldin Award Winner Advocates Online Education

Latest News

Polypoidal Choroidal Vasculopathy: Treatment Comparison and Massive Submacular Hemorrhage Incidence

Ophthalmology

Two poster presentations to be shared at AAO 2019 will aim to shed light on polypoidal choroidal vasculopathy (PCV) treatments and adverse events. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe